Covid-19 vaccine: Pfizer announces 90% efficacy based on preliminary result

Pfizer (USA) and BioNTech (Germany) announced on November 9 that their Phase 3 clinical trial had undergone a first interim evaluation after 94 participants were infected with Sars CoV-2. Their candidate vaccine would be 90% effective in preventing coronavirus infection in people who have never previously contracted covid-19. The trial is ongoing and will need to provide more data before it can be considered for emergency licensure. Application is expected by the third week of November.

Leave a Reply

Your email address will not be published. Required fields are marked *